Showing results (2121-2130 of 2,232) with videos related to
Sort By:
Pageof 224
Journal of Virological Methods|January 25, 2022
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utilityCarolina Rosadas, Maryam Khan, Eleanor Parker, et al.Disaster Medicine and Public Health Preparedness|June 18, 2019
Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Science and the CBRNE Science Medical Operations Science Support Expert (CMOSSE)C Norman Coleman, Judith L Bader, John F Koerner, et al.Cell|June 9, 2023
High-resolution analyses of associations between medications, microbiome, and mortality in cancer patientsChi L Nguyen, Kate A Markey, Oriana Miltiadous, et al.Science (New York, N.Y.)|July 4, 2009
H2O at the Phoenix landing siteP H Smith, L K Tamppari, R E Arvidson, et al.Thorax|August 16, 2020
Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence surveyBarnaby Flower, Jonathan C Brown, Bryony Simmons, et al.Science Advances|April 23, 2021
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunityAnnachiara Rosa, Valerie E Pye, Carl Graham, et al.Aging Clinical and Experimental Research|June 21, 2013
Ascertainment bias in dementias: a secondary to tertiary centre analysis in Central Italy and conceptual reviewL Bonanni, G Bontempo, I Borrelli, et al.Medrxiv : the Preprint Server for Health Sciences|February 3, 2021
SARS-CoV-2 recruits a haem metabolite to evade antibody immunityAnnachiara Rosa, Valerie E Pye, Carl Graham, et al.Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.Pageof 224